

BAXTER INTERNATIONAL INC.
Reconciliation of GAAP to Non-GAAP Net Sales Measures
Periods Ending June 30, 2011 and 2010
(unaudited)
(\$ in millions)

The company's GAAP net sales results for the six months ended June 30, 2010 included a \$213 million charge related to the recall of COLLEAGUE infusion pumps, which impacted GAAP net sales as follows:

	2011 YTD			2010 YTD			% Growth @ Actual Rates			% Growth @ Constant Rates		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
Infusion Systems - GAAP			\$444			\$212			110%			106%
COLLEAGUE infusion pump charge						213						
Infusion Systems - Adjusted			\$444			\$425			4%			3%
Total Medical Products - GAAP	\$1,452	\$2,389	\$3,841	\$1,171	\$2,206	\$3,377	24%	8%	14%	24%	4%	11%
COLLEAGUE infusion pump charge				213		213						
Total Medical Products - Adjusted	\$1,452	\$2,389	\$3,841	\$1,384	\$2,206	\$3,590	5%	8%	7%	5%	4%	4%
Total Baxter - GAAP	\$2,840	\$3,980	\$6,820	\$2,435	\$3,686	\$6,121	17%	8%	11%	17%	4%	9%
COLLEAGUE infusion pump charge				213		213						
Total Baxter - Adjusted	\$2,840	\$3,980	\$6,820	\$2,648	\$3,686	\$6,334	7%	8%	8%	7%	4%	5%

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.